RecruitingNCT06783127

Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer

Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer: An Observational Study

Sponsor

Santa Chiara Hospital

Enrollment

3,000 participants

Start Date

Jan 1, 2023

Study Type

OBSERVATIONAL

Conditions

Prostate Cancer BRCA Mutation Castrate Resistant Prostate Cancer

Summary

This is an observational, retrospective/prospective, multicenter study designed to define, overall survival, clinical outcomes and predictive/prognostic factors of a consecutive population of mCRPC patients treated with olaparib in clinical practice.

Eligibility

Sex: MALE

Plain Language Summary

Simplified for easier understanding

This observational study is reviewing real-world clinical outcomes of men with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) who were treated with olaparib — a targeted PARP inhibitor drug — in routine clinical practice rather than in a trial setting. **You may be eligible if...** - You are a male patient with metastatic castration-resistant prostate cancer - You have a BRCA gene mutation (hereditary or tumor-based) - You received olaparib as part of routine clinical care (not a clinical trial) **You may NOT be eligible if...** - You received olaparib within the context of a clinical trial Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.